Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer With Abiraterone or Enzalutamide

[kainasar]

Forest Riekhof et al. Clin Genitourin Cancer. 2023.

Abstract

Background: Abiraterone and enzalutamide are second generation androgen receptor pathway inhibitors (ARPIs) used to treat advanced or metastatic prostate cancer. Without head-to-head comparative studies identifying 1 agent as preferred initial therapy, physician preferences guide initial ARPI choice. This study compares hospitalizations among patients treated initially with abiraterone versus enzalutamide.

Total rate of hospitalization increased 22% for abiraterone compared to a 3% increase for enzalutamide in the 12 months after ARPI initiation (P < .0001). Abiraterone was associated with greater increase in rates of acute heart failure, atrial fibrillation, acute kidney injury, urinary tract infections, sepsis, and pneumonia.

pubmed.ncbi.nlm.nih.gov/374...

[reconjj]

Interesting article . Yes Im a Veteran being treated at Hines V.A. hospital in Illinois . Im 18 months on Eligard , Zytiga ( abi ) and prednisone and starting to notice heart issues . So I might have the talk to my V.A. MO. Thanks , SemperFi , JJ

[RCOG2000]

thank you for sharing this extremely important information. Not a placebo controlled randomized trial but the effect size snd sample size are certainly large enough yo looks closely for any moderator variables that might account for the difference

[Rojoho]

I've been on Abiraterone for almost 3 years. I may want to try enzalutamide when abiraterone stops working. If I do my out of pocket expenses will go up by thousands of dollars per year. I will keep a close I on my heart, kidney and liver function, but continue my current course.